Sponsors (3)
The bill strengthens enforcement, coordination, and data-driven prevention against counterfeit fentanyl/meth pills—potentially reducing supply and accidental overdoses—but increases criminal-liability risk for unwitting sellers, raises economic and operational costs, and may expand punitive policing rather than prioritize treatment.
Law enforcement and prosecutors will have clearer definitions, coordinated strategies, and centralized annual data to better identify, seize, and prosecute counterfeit fentanyl/methamphetamine pills, improving supply disruption and federal oversight.
Parents, children, and teens will benefit from audited, data-driven, youth-targeted prevention and public-education campaigns that are reviewed and adjusted to reduce accidental ingestion and overdoses.
Prosecutors and courts will have clearer statutory language around counterfeit drug offenses and certain Controlled Substances Act provisions, improving enforcement consistency and potentially speeding investigations.
Low-income individuals, small sellers, and others who unknowingly handle contaminated or misbranded products could face expanded criminal liability and increased risk of prosecution due to broader statutory definitions.
Small businesses and taxpayers may bear higher economic costs from increased compliance burdens, seizure risk for legitimately labeled/contaminated goods, and higher operational/reporting costs for federal agencies producing required reports.
Communities — particularly marginalized neighborhoods — could experience expanded policing and criminalization as emphasis shifts toward enforcement of counterfeit drug provisions instead of treatment-oriented responses.
Based on analysis of 5 sections of legislative text.
Requires DEA operational plan and annual DOJ reports focused on counterfeit fentanyl/methamphetamine seizures, prosecutions, and prevention; defines covered counterfeit substances.
Official title: Amend the Controlled Substances Act to prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances, and for other purposes.
Introduced October 30, 2025 by Charles Ernest Grassley · Last progress October 30, 2025
Requires the DEA to define “counterfeit fentanyl or methamphetamine substance,” create an operational and response plan within 180 days to guide enforcement, seizures, education, and prevention efforts, and directs DOJ (with DEA and ONDCP) to produce annual reports on seizures, prosecutions, and prevention activities. Also amends the Controlled Substances Act’s prohibited acts language to cover substances marketed or sold as other products when they contain fentanyl, fentanyl analogues, or methamphetamine. The law focuses on improving federal law enforcement coordination, auditing and tailoring public awareness campaigns (including youth-focused efforts), and increasing data collection and transparency about pill-form counterfeit stimulant and opioid seizures and related prosecutions.